Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Neuroleptic

or [[:Category:Basal_insulins|Basal insulin]]

Use the filters below to narrow your results.

Asenapine (1) · Butorphanol (1) · Chlorpromazine (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Droperidol (1) · Ethylmorphine (1) · Fentanyl (1) · Fluphenazine (1) · Hydrocodone (1) · Hydromorphone (1) · Iloperidone (1) · Insulin degludec (1) · Insulin detemir (1) · Insulin glargine (1) · Levorphanol (1) · Loxapine (1) · Lurasidone (1) · Meperidine (1) · Molindone (1) · Nalbuphine (1) · Oxymorphone (1) · Paliperidone (1) · Papaverine (1) · Pentazocine (1) · Perphenazine (1) · Pimozide (1) · Tapentadol (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)

None (5) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Lantus, Basaglar, Semglee, Toujeo (U-300) (1) · Latuda (1) · Levemir, Levemir FlexTouch (US discontinuation announced 2024) (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nubain (1) · Nucynta (1) · Opana (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stadol (1) · Stelazine (1) · Talwin (1) · Thorazine (1) · Tresiba (1) · Trilafon (1) · Vicodin (1)

None (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Phenothiazine D2 antagonist (4) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) · '"`UNIQ--vote-00001356-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio'"`UNIQ--ref-00001357-QINU`"'. (1)

None (30) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) · '"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1) · '"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)

None (30) · Adult: 15–60 mg every 4 hours as needed. (1) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)

None (30) · 100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) · 100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) · 100 U/mL FlexTouch pen, vial (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (30) · 360 mg/day (1) · Titrated to glucose (1) · Titrated to glucose; no fixed ceiling (2)

None (30) · PO (only formulation marketed in the US). (1) · Subcutaneous (1) · Subcutaneous (never IV; not for use in insulin pumps) (2)

None (30) · 1-2 hours (2) · 30–60 min (PO) (1) · ~1 hour (1)

None (30) · 4–6 hours (1) · >42 hours per dose (effectively flat once at steady state) (1) · ~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1) · ~24 hours per dose (peakless profile by design) (1)

None (30) · 2.5–3 hours (1) · ~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) · ~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) · ~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)

None (30) · ~100% from subcutaneous depot (1) · ~100% from subcutaneous depot (by definition of the route) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)

None (30) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · One of the better-studied basal insulin analogs in pregnancy; reassuring data.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (30) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (3)